Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Alto Neuroscience (ANRO) · oqro.io/stocks/ANRO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Have Alto Neuroscience insiders bought shares recently?
No open-market purchase by an insider of Alto Neuroscience was filed in the last 90 days. The latest on record was on Jul 10, 2024.
How often do Alto Neuroscience insiders buy and sell shares?
Since 2024, Alto Neuroscience insiders reported 9 open-market purchases and 8 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2024.
Who is selling Alto Neuroscience stock?
In the last 90 days, 2 insiders of Alto Neuroscience (ANRO) reported 8 open-market sales worth $5.64M in total on SEC Form 4. The largest seller by value was Nicholas Conrad Smith, with $3.57M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade ANRO?
No trade in Alto Neuroscience (ANRO) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+79.3% (+$11.22) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $14.15 on Nov 20, 2025 to $25.37 on Nov 20, 2026 (+79.3%). Disclosed in this range: 0 insider trades, 8 pre-arranged insider sales, 0 Congress trades, and 3 13F position changes for 3 quarters ending in it.
$10$15$20$30$35$40$25.37
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 8 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Mountain View, Ca.
Last 12 months
+70.6%
S&P 500 +8.0% over the same dates
Market value
$1.06B
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5.68M shares sold short (14.2% of shares outstanding), +9.2% vs the previous count, 10.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Alto Neuroscience over the 12 months to Nov 20, 2026: 4 clinical trials.
Insider buying and selling since 2024
Insiders of Alto Neuroscience reported 9 open-market purchases and 8 sales since 2024; purchases in 2024.
Year
Bought
Sold
2026
—
$5.64M8×8 trades
2024
$10.2M9×9 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last 30 days
Written by software from the filings listed below · Oct 26, 2026
Insiders. In the 30 days to Oct 26, 2026, Alto Neuroscience insiders filed 0 open-market purchases and 3 open-market sales (about $3.57M, in 1 filing, by 1 person). Alto Neuroscience on OQRO
3 more points, with the facts they come from, are in OQRO Pro.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Late-stage clinical trials
0 active phase 3 trials and 4 active phase 2 trials led by this company, mostly in schizophrenia, major depressive disorder, bipolar disorder i or ii with a major depressive episode. The ones with the nearest registered primary completion date still ahead:
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Alto Neuroscience filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 8 open-market sales (about $5.64M, in 2 filings, by 2 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 0 open-market sales (about $0, in 0 filings). (Alto Neuroscience on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 2 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. ClinicalTrials.gov shows 4 studys sponsored by the company updated in the period; the latest, "Study of ALTO-300 in MDD" (Phase 2, status recruiting), was updated on Oct 26, 2026, with primary completion listed for 2026-12. FINRA short interest for ANRO on the settlement date of Oct 30, 2026 was 5,682,860 shares (+9.19% on the previous report), about 10.51 days of average volume.
Company reports, price and press. Alto Neuroscience filed a Form 8-K on Aug 27, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member. The company's own opening sentence of that report reads: "On August 26, 2026 (the ' Effective Date' ), the Board of Directors (the ' Board ') of Alto Neuroscience, Inc. (the ' Company ') promoted Nicholas C. Smith, the Company’s Chief Financial Officer and Chief Business Officer, to the..."
Who holds it. 114 funds reported a stake in Alto Neuroscience in their 13F for Q2 2026. The largest by value: Alpha Wave Global, LP (12.6% of the value reported), Commodore Capital LP (9.2% of the value reported), BlackRock, Inc. (7.2% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Alto Neuroscience filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 8 open-market sales (about $5.64M, in 2 filings, by 2 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 0 open-market sales (about $0, in 0 filings).
The largest sale: Nicholas Conrad Smith, PRESIDENT AND CFO, about $2.95M, filed Oct 2, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 2 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
ClinicalTrials.gov shows 4 studys sponsored by the company updated in the period; the latest, "Study of ALTO-300 in MDD" (Phase 2, status recruiting), was updated on Oct 26, 2026, with primary completion listed for 2026-12.
FINRA short interest for ANRO on the settlement date of Oct 30, 2026 was 5,682,860 shares (+9.19% on the previous report), about 10.51 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Orbimed Advisors LLC (increased, 90,352 shares); the largest that shrank: Jennison Associates LLC (sold out); Polen Capital Management LLC (sold out). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Alto Neuroscience filed a Form 8-K on Aug 27, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On August 26, 2026 (the ' Effective Date' ), the Board of Directors (the ' Board ') of Alto Neuroscience, Inc. (the ' Company ') promoted Nicholas C. Smith, the Company’s Chief Financial Officer and Chief Business Officer, to the..."
Alto Neuroscience filed a Form 8-K on May 28, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "Effective March 16, 2026, the Board had increased its size from six to seven directors, and Dr. Miller will join the board and fill the resulting vacancy. Dr. Miller was appointed as a Class III director for a term expiring at th..."
Alto Neuroscience filed a Form 8-K on May 13, 2026 (Items 5.02, 5.07) that OQRO classes as: changed a top executive or board member, and held a shareholder vote.
The company's own opening sentence of that report reads: "(e) Equity Plan Amendments As noted in Item 5.07 below, at the Alto Neuroscience, Inc. (the 'Company') 2026 annual meeting of stockholders (the 'Annual Meeting'), the Company’s stockholders approved the Amended and Restated 2024..."
Press coverage listed by Finnhub: "Alto Neuroscience faces pivotal 2027 as Jefferies flags three clinical catalysts" (Yahoo, Nov 11, 2026).
Press coverage listed by Finnhub: "Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights" (Yahoo, Nov 10, 2026).
Press coverage listed by Finnhub: "Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08" (Yahoo, Nov 4, 2026).
ANRO closed at $25.91 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $22.82 to $25.91, a change of +13.5%.
Who holds it
114 funds reported a stake in Alto Neuroscience in their 13F for Q2 2026. The largest by value: Alpha Wave Global, LP (12.6% of the value reported), Commodore Capital LP (9.2% of the value reported), BlackRock, Inc. (7.2% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
From “Overview”, in the company's words
We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Through insights derived from our scalable and proprietary Platform, we aim to discover brain-based biomarkers to better identify which patients are more likely to respond to our novel product candidates. Our current pipeline consists of seven clinical-stage assets addressing high-need therapeutic areas, including MDD, BPD, TRD, schizophrenia, and Parkinson’s disease.
What the section covers (25 headings)
Overview
License and Other Agreements
Components of Results of Operations
Operating Expenses
Research and Development Expenses
General and Administrative Expenses
Other Income (Expense)
Results of Operations
Comparison of the Years Ended December 31, 2025 and 2024
Liquidity and Capital Resources
Amended Loan and Security Agreement
Convertible Grant Agreement
Shelf Registration Statement
Cash Flows
And 11 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 16, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 38.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (28.9% on ATS, 9.9% with other brokers), close to its 26-week average of 40.3%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: SIGMA X2 (15.9%), UBS ATS (13.1%), INTELLIGENT CROSS LLC (9.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Mar 16, 2026, compared with the one filed Mar 20, 2025. Read the filing
New risk factors in the latest annual report (3 headings)
If the FDA does not conclude that ALTO-207 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements under Section 505(b)(2) are not as we expect, the approval pathway for ALTO-207 will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated and may not be successful.
If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed.
We are currently subject to and may be subject to additional future securities class action litigation.
No longer listed (1 heading from the year before)
We may be subject to securities litigation, which is expensive and could divert management attention.
Legal proceedings (Item 3)
Information pertaining to legal proceedings can be found in Part II of this Annual Report under “Item 8. Financial Statements and Supplementary Data - Note 15. Commitments and Contingencies” and is incorporated by reference herein. In addition, from time to time, we may be involved in legal proceedings arising in the ordinary course of business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Mar 16, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.